<DOC>
	<DOCNO>NCT00000637</DOCNO>
	<brief_summary>To compare effectiveness treatment zidovudine ( AZT ) compare didanosine ( ddI ) compare combination AZT ddI determine survival disease progression . To compare relative safety tolerance AZT versus ddI versus AZT plus ddI symptomatic HIV infect child ; compare virological immunological parameter three treatment group . AZT show delay progression AIDS HIV infected individual . However , bone marrow toxicity frequent adverse effect . Also , HIV resistance AZT sometimes occur patient initially respond treatment , later progression disease . Thus , new drug treatment need . Studies ddI adult child indicate effectiveness drug . A direct comparison AZT ddI treatment child make . Combination antiviral treatment ( AZT plus ddI ) may give added therapeutic benefit child .</brief_summary>
	<brief_title>A Randomized Comparative Trial Zidovudine ( AZT ) Versus 2',3'-Dideoxyinosine ( ddI ) Versus AZT Plus ddI Symptomatic HIV-Infected Children</brief_title>
	<detailed_description>AZT show delay progression AIDS HIV infected individual . However , bone marrow toxicity frequent adverse effect . Also , HIV resistance AZT sometimes occur patient initially respond treatment , later progression disease . Thus , new drug treatment need . Studies ddI adult child indicate effectiveness drug . A direct comparison AZT ddI treatment child make . Combination antiviral treatment ( AZT plus ddI ) may give added therapeutic benefit child . Patients place random selection one three group receive either AZT alone , ddI alone , AZT ddI . This double-blind study : neither patient treat physician know group patient . If patient receive either AZT ddI alone develop drug toxicity ( dose reduction ) , HIV disease progress , alternative single drug offer . If patient receive drug develop drug toxicity ( despite dose reduction ) HIV disease progress , discontinue study drug offer best alternative therapy . PER AMENDMENT 6/26/95 : Initial monotherapy AZT arm unblinded crossover therapy arm permit . Patients reach crossover criteria initial blind ddI AZT+ddI unblinded permanently discontinue study drug .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acetaminophen , ibuprofen , aspirin , continual basis &gt; 72 hour . Systemic ketoconazole fluconazole acute therapy . Recommended : Prophylaxis PCP . ( Primary prophylaxis TMP / SMX encourage . ) IV pentamidine may use select case administer weekly basis . Patients must follow : HIV infection . Children randomize prior eighteenth birthday eligible . Coenrollment either ACTG 179 189 permit . Prior Medication : Allowed : Up six week antiretroviral immunomodulator treatment exclude steroid intravenous immunoglobulin . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active malignancy . Pancreatitis history pancreatitis within one year prior study entry associate compatible symptom . History uncontrolled seizure disorder . Grade 3 high peripheral neuropathy . Cardiomyopathy . Concurrent Medication : Excluded : Chemotherapy malignancy . Oral acidify agent . Acetaminophen , ibuprofen , aspirin continual basis &gt; 72 hour . Ketoconazole fluconazole prophylaxis . Drugs potential cause peripheral neuropathy pancreatitis give daily &gt; 4 week . Patients follow exclude : Active malignancy . Pancreatitis history pancreatitis within one year prior study entry associate compatible symptom . History uncontrolled seizure disorder . Grade 3 high peripheral neuropathy . Prior Medication : Excluded : Steroids . Intravenous immunoglobulin . Antiretroviral drug specific immunomodulator treatment ( exclude steroid intravenous immunoglobulin ) &gt; 6 week within 7 day prior study entry . Prior Treatment : Excluded : Red blood cell transfusion within four week prior study entry . Ongoing drug alcohol use .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>